Blockade of mitogen-activated protein kinase cascade signaling in interleukin 6-independent multiple myeloma cells

Related Experiment Video

Updated: Aug 11, 2026

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

A Ogata1, D Chauhan, M Urashima

  • 1Division of Hematologic Malignancies, Dana-Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02215, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|June 1, 1997
PubMed

Insights

Interleukin 6 (IL-6) promotes multiple myeloma (MM) cell growth via the MAPK pathway. Loss of IL-6 responsiveness in MM cells is linked to impaired Sos1 activation, a key step in the MAPK cascade.

Area of Science:

  • Cancer Biology
  • Cell Signaling
  • Molecular Oncology

Background:

  • Interleukin 6 (IL-6) is a critical growth factor for multiple myeloma (MM) cells.
  • IL-6 signaling involves the Ras-dependent mitogen-activated protein kinase (MAPK) pathway.
  • Not all MM cells are dependent on IL-6 for proliferation.

Purpose of the Study:

  • To investigate the upstream activation of the MAPK cascade in IL-6-responsive and non-responsive MM cells.
  • To identify specific blockade points in the MAPK pathway contributing to IL-6 independence in MM.

Main Methods:

  • Comparative analysis of MAPK pathway activation in IL-6-responsive (B9) and IL-6-nonresponsive (U266, OCI-My5, RPMI8226) MM cell lines.
  • Assessment of protein phosphorylation and complex formation at key signaling nodes (gp130, PTP1D, Grb2, Sos1).

Main Results:

  • IL-6 induced sequential activation of gp130, PTP1D, and Sos1 in IL-6-responsive B9 cells.
  • IL-6-independent MM cells showed varying defects in MAPK activation, notably impaired Sos1 phosphorylation.
  • OCI-My5 cells lacked Grb2-Sos1 association, while U266 and RPMI8226 cells had constitutive Grb2-Sos1 association but no IL-6-induced Sos1 phosphorylation.

Conclusions:

  • The study identifies impaired Sos1 activation as a critical factor associated with IL-6 independence in multiple myeloma.
  • These findings highlight specific molecular events in the MAPK pathway that dictate IL-6 responsiveness in MM cells.

More Related Videos

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity07:09

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Published on: January 7, 2019

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...